163 related articles for article (PubMed ID: 8618827)
21. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
22. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors.
Hornick JL; Sharifi J; Khawli LA; Hu P; Bai WG; Alauddin MM; Mizokami MM; Epstein AL
J Nucl Med; 2000 Feb; 41(2):355-62. PubMed ID: 10688122
[TBL] [Abstract][Full Text] [Related]
23. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H.
Boyd PN; Lines AC; Patel AK
Mol Immunol; 1995 Dec; 32(17-18):1311-8. PubMed ID: 8643100
[TBL] [Abstract][Full Text] [Related]
24. A CDR-grafted (humanized) domain-deleted antitumor antibody.
Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
27. Endogenous anti-tumor antibody responses in nude mice.
Stigbrand T; Ullén A; Sandström P; Rathsman S; Rossi Norrlund R; Arlestig L; Riklund Ahlström K; Hietala SO
Cancer; 1997 Dec; 80(12 Suppl):2404-10. PubMed ID: 9406690
[TBL] [Abstract][Full Text] [Related]
28. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of CAMPATH-1H: assay development and validation.
Rebello P; Hale G
J Immunol Methods; 2002 Feb; 260(1-2):285-302. PubMed ID: 11792397
[TBL] [Abstract][Full Text] [Related]
30. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
31. Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumor xenografts.
Demignot S; Pimm MV; Baldwin RW
Cancer Res; 1990 May; 50(10):2936-42. PubMed ID: 2334894
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity.
Kobayashi H; Sato N; Saga T; Nakamoto Y; Ishimori T; Toyama S; Togashi K; Konishi J; Brechbiel MW
Eur J Nucl Med; 2000 Sep; 27(9):1334-9. PubMed ID: 11007515
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors.
Sharifi J; Khawli LA; Hu P; King S; Epstein AL
Hybrid Hybridomics; 2001; 20(5-6):305-12. PubMed ID: 11839248
[TBL] [Abstract][Full Text] [Related]
34. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
35. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
[TBL] [Abstract][Full Text] [Related]
37. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
[TBL] [Abstract][Full Text] [Related]
38. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
Kenanova V; Olafsen T; Crow DM; Sundaresan G; Subbarayan M; Carter NH; Ikle DN; Yazaki PJ; Chatziioannou AF; Gambhir SS; Williams LE; Shively JE; Colcher D; Raubitschek AA; Wu AM
Cancer Res; 2005 Jan; 65(2):622-31. PubMed ID: 15695407
[TBL] [Abstract][Full Text] [Related]
39. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
40. Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.
Mitchell P; Lee FT; Hall C; Rigopoulos A; Smyth FE; Hekman AM; van Schijndel GM; Powles R; Brechbiel MW; Scott AM
J Nucl Med; 2003 Jul; 44(7):1105-12. PubMed ID: 12843229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
